Corrigendum to “Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines” [Vaccine 34 (2016) 757–761]  by Van Damme, Pierre et al.
Vaccine 34 (2016) 4759–4760Contents lists available at ScienceDirect
Vaccine
journal homepage: www.elsevier .com/locate /vacc ineCorrigendumCorrigendum to ‘‘Use of the nonavalent HPV vaccine in individuals
previously fully or partially vaccinated with bivalent or quadrivalent
HPV vaccines” [Vaccine 34 (2016) 757–761]http://dx.doi.org/10.1016/j.vaccine.2016.07.035
0264-410X/ 2016 The Author(s). Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
DOI of original article: http://dx.doi.org/10.1016/j.vaccine.2015.12.063
⇑ Corresponding author. Tel.: +32 32652538; fax: +32 32652640.
E-mail address: pierre.vandamme@uantwerp.be (P. Van Damme).Pierre Van Damme a,⇑, Paolo Bonanni b, F. Xavier Bosch c, Elmar Joura d, Susanne Krüger Kjaer e,
Chris J.L.M. Meijer f, Karl-Ulrich Petry g, Benoit Soubeyrand h, Thomas Verstraeten i, Margaret Stanley j
aCentre for Evaluation of Vaccination, Vaccine and Infectious Diseases Institute, University of Antwerp, Antwerp, Belgium
bDepartment of Health Sciences, University of Florence, Florence, Italy
cCancer Research Epidemiology Program, Catalan Institute of Oncology, IDIBELL, Barcelona, Spain
dDepartment of Obstetrics and Gynecology, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria
eDepartment of Gynaecology, Juliane Marie Centre, Rigshospitalet, Copenhagen University Hospital and the University of Copenhagen, Copenhagen, Denmark
fDepartment of Pathology, Free University Medical Center, Amsterdam, The Netherlands
gDepartment of Gynaecology and Obstetrics, Klinikum Wolfsburg, Wolfsburg, Germany
h Sanofi Pasteur MSD, Department of Medical Affairs, Lyon, France
iP95, Epidemiology and Pharmacovigilance Consulting and Services, Leuven, Belgium
jDepartment of Pathology, Cambridge University, Cambridge, UKThe authors regret that an error occurred in Table 1 and the text
‘‘no evidence” should be replaced by ‘‘incomplete”. The corrected
version of Table 1 is reproduced below.The authors would like to apologise for any inconvenience
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Table 1
Scenarios and proposed approaches, for girls 9–14 years of age.
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